International Journal of Radiation Oncology*Biology*Physics
Poster Viewing AbstractCost Effectiveness of Radiotherapy in Locally Advanced Pancreatic Cancer
Section snippets
Purpose/Objective(s)
To evaluate the cost-effectiveness of radiotherapy in locally advanced pancreatic cancer.
Materials/Methods
A Markov decision-analytic model was constructed to compare the cost-effectiveness of four treatment regimens: gemcitabine (gem) alone, gem plus conventional radiotherapy, gem plus intensity modulated radiotherapy (IMRT), and gem with stereotactic body radiotherapy (SBRT). Patients were allowed to transition between the following three health states: stable disease, progressive disease, and death. Patients were assessed health utility tolls for radiotherapy and chemotherapy treatments, and
Results
SBRT increased life expectancy by 0.171 quality adjusted life years (QALY) at an increased cost of $13,744 compared with gem alone (incremental cost-effectiveness ratio [ICER] = $80,131/QALY). The ICER of conventional radiotherapy compared to gem alone was $134,965/QALY. The ICER of IMRT compared to conventional radiotherapy was $2,083,882/QALY. The model was most sensitive to survival. The ICER of SBRT increased above $100,000/QALY when the mean survival of gem-alone increased by more than
Conclusions
SBRT plus gemcitabine is a cost-effective treatment option compared with gemcitabine alone in locally advanced pancreatic cancer.
References (0)
Cited by (0)
Author Disclosure: J.D. Murphy, None; D.T. Chang, None; J. Abelson, None; M.E. Daly, None; H.N. Yeung, None; L.M. Nelson, None; A.C. Koong, None.